Neurocrine’s Tardive Dyskinesia Opportunity Could Support a Multi-Year Growth Runway
Neurocrine’s estimated 800,000-person tardive dyskinesia population could support years of prescription growth, but execution remains key.
Parabilis’ FDA Alignment Gives Its Desmoid Tumor Program a Clearer Road Map
Parabilis’ FDA-aligned dose strategy and placebo-controlled pivotal trial design may reduce uncertai…
Compass Therapeutics’ Tovecimig Data Published in Journal of Clinical Oncology
Peer-reviewed publication of Compass Therapeutics’ Phase 2/3 tovecimig study may shape investor sent…
Zymeworks’ ZW191 Posts Strong Response Rates in Platinum-Resistant Ovarian Cancer
ZW191 produced confirmed response rates of 64.5% and 55.3% in a difficult-to-treat ovarian cancer tr…
American Express’ 5% Workforce Cut Puts Cost Discipline in the Spotlight
American Express will cut 5% of its workforce and record a $336 million restructuring charge after a…
Teva's FDA Approval Adds a Fresh Catalyst for Healthcare Investors
Teva drew attention after an FDA approval, but its quoted price later stood at $40.21, down 1.009%, …
Tango Therapeutics Slides 13% Despite 82% Pancreatic Cancer Response Rate
Tango Therapeutics fell 13% despite an 82% response rate, highlighting how traders discount small-sa…
Elicio’s Pancreatic Cancer Trial Misses Endpoint Despite Positive Subgroup Signal
Elicio’s Phase 2 pancreatic cancer trial missed its primary endpoint, while a subgroup signal raises…
IDEAYA’s IDE849 Data Put Dose, Safety and Pipeline Economics in Focus
IDE849’s Grade 3+ adverse-event rates rose from 5% to 22.2% across doses, sharpening questions about…
Rapport Director Buys Nearly $1 Million as Analyst Raises Price Target to $82
Insider buying and a higher $82 price target put Rapport Therapeutics’ clinical pipeline under the m…